Surmodics Inc
NASDAQ:SRDX
Intrinsic Value
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. [ Read More ]
The intrinsic value of one SRDX stock under the Base Case scenario is 21.51 USD. Compared to the current market price of 26.07 USD, Surmodics Inc is Overvalued by 17%.
Valuation Backtest
Surmodics Inc
Run backtest to discover the historical profit from buying and selling SRDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Surmodics Inc
Current Assets | 79.8m |
Cash & Short-Term Investments | 35.2m |
Receivables | 23.1m |
Other Current Assets | 21.5m |
Non-Current Assets | 100.4m |
PP&E | 29.2m |
Intangibles | 70.5m |
Other Non-Current Assets | 724k |
Current Liabilities | 16.5m |
Accounts Payable | 2.6m |
Accrued Liabilities | 9.9m |
Other Current Liabilities | 4m |
Non-Current Liabilities | 41.6m |
Long-Term Debt | 29.4m |
Other Non-Current Liabilities | 12.2m |
Earnings Waterfall
Surmodics Inc
Revenue
|
138.2m
USD
|
Cost of Revenue
|
-28.5m
USD
|
Gross Profit
|
109.7m
USD
|
Operating Expenses
|
-97.6m
USD
|
Operating Income
|
12.1m
USD
|
Other Expenses
|
-6.5m
USD
|
Net Income
|
5.5m
USD
|
Free Cash Flow Analysis
Surmodics Inc
SRDX Profitability Score
Profitability Due Diligence
Surmodics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Surmodics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
SRDX Solvency Score
Solvency Due Diligence
Surmodics Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Surmodics Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SRDX Price Targets Summary
Surmodics Inc
According to Wall Street analysts, the average 1-year price target for SRDX is 60.18 USD with a low forecast of 44.44 USD and a high forecast of 78.75 USD.
Ownership
SRDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SRDX Price
Surmodics Inc
Average Annual Return | -3.63% |
Standard Deviation of Annual Returns | 20.17% |
Max Drawdown | -72% |
Market Capitalization | 371.1m USD |
Shares Outstanding | 14 240 000 |
Percentage of Shares Shorted | 3.95% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.
Contact
IPO
Employees
Officers
The intrinsic value of one SRDX stock under the Base Case scenario is 21.51 USD.
Compared to the current market price of 26.07 USD, Surmodics Inc is Overvalued by 17%.